Valuation: C4 Therapeutics, Inc.

Market Cap 41Cr 36Cr 33Cr 30Cr 57Cr 3.85TCr 58Cr 398.84Cr 160.11Cr 2.03TCr 152.36Cr 149.12Cr 6.39TCr P/E 2026 *
-3.94x
P/E 2027 * -3.6x
Enterprise Value 32Cr 29Cr 27Cr 24Cr 45Cr 3.08TCr 46Cr 318.98Cr 128.05Cr 1.62TCr 121.85Cr 119.26Cr 5.11TCr EV / Sales 2026 *
12.3x
EV / Sales 2027 * 12.9x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+0.45%
1 week+8.01%
Current month-0.75%
1 month-0.75%
3 months-9.70%
6 months+16.78%
Current year+73.04%
1 week 2.94
Extreme 2.94
3.53
1 month 2.59
Extreme 2.59
3.53
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Founder

3,662 0.0030%
01/10/26 Free

Director

4,618 0.0038%
18/09/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+8.01%+34.35%+118.87% 41Cr
-0.62%+0.50%+33.92%+60.07% 6.44TCr
+0.35%+3.20%+14.92%+84.55% 5.62TCr
+0.53%+1.96%+15.37%+106.81% 5.42TCr
-3.20%-5.01%+22.59%+49.79% 4.53TCr
-0.59%-2.09%+19.96%+98.13% 4.22TCr
+0.39%+1.72%+223.08%+936.51% 4.08TCr
+3.27%+47.96%+112.67%+96.48% 3.38TCr
+1.22%-1.39%+13.92%+46.95% 3.22TCr
-1.29%-1.72%+21.00%-6.85% 2.36TCr
Average +0.04%+4.63%+51.18%+159.13% 3.93TCr
Weighted average by Cap. -0.08%+3.64%+49.82%+161.94%

Financials

2026 *2027 *
Net sales 2.63Cr 2.36Cr 2.17Cr 1.96Cr 3.67Cr 249.89Cr 3.74Cr 26Cr 10Cr 131.45Cr 9.88Cr 9.67Cr 414.54Cr 2.24Cr 2.01Cr 1.85Cr 1.67Cr 3.13Cr 212.95Cr 3.19Cr 22Cr 8.84Cr 112.02Cr 8.42Cr 8.24Cr 353.27Cr
Net income -11Cr -9.93Cr -9.13Cr -8.28Cr -15Cr -1.05TCr -16Cr -108.91Cr -44Cr -553.74Cr -42Cr -41Cr -1.75TCr -14Cr -13Cr -12Cr -11Cr -20Cr -1.34TCr -20Cr -138.35Cr -56Cr -703.4Cr -53Cr -52Cr -2.22TCr
Net Debt -8.13Cr -7.28Cr -6.7Cr -6.07Cr -11Cr -771.85Cr -12Cr -80Cr -32Cr -406.02Cr -31Cr -30Cr -1.28TCr -12Cr -10Cr -9.65Cr -8.74Cr -16Cr -1.11TCr -17Cr -115.09Cr -46Cr -585.13Cr -44Cr -43Cr -1.85TCr
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
31/26/31 $3.300 0.00% 16,37,413
29/26/29 $3.300 -2.80% 27,15,031
28/26/28 $3.395 +5.76% 41,10,813
27/26/27 $3.210 +7.72% 41,19,734
26/26/26 $2.980 -2.61% 31,79,137
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.300USD
Average target price
12.62USD
Spread / Average Target
+282.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock